Articles related to PANCREATIC CANCER
FDA Approves Irinotecan Liposome Combo in Metastatic Pancreatic Cancer
The FDA’s approval of irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin marks a pivotal advancement in first-line treatment options for metastatic pancreatic adenocarcinoma, showcasing a notable increase in overall and progression-free survival rates.
Hematology/Oncology February 20th 2024
Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer
In a recent phase II trial, patients with untreated metastatic pancreatic ductal adenocarcinoma receiving sequential nab-P/Gem-mFOLFOX experienced a median overall survival of 13.2 months, compared to 9.7 months in those receiving standard nab-P/Gem treatment, indicating a notable improvement in survival outcomes.
Oncology, Medical February 5th 2024
FDA Drug Approval Decisions Expected in February 2024
Explore groundbreaking therapies in the pipeline: Onivyde for pancreatic cancer, showing marked survival benefits, and roluperidone, offering new hope in managing schizophrenia’s negative symptoms.
Hematology/Oncology January 22nd 2024
Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2023 (CME)
Take part in an engaging multidisciplinary discussion on the evolving dynamics of hepato-pancreatico-biliary cancers. Discover, learn, and prepare to integrate these new strategies into your clinical practice.
Oncology, Medical July 18th 2023
Neoadjuvant FOLFIRINOX Does Not Improve OS in Resectable Pancreatic Cancer
Neoadjuvant Chemotherapy and Upfront Surgery: A Comparative Study in Resectable Pancreatic Cancer In a recent study presented at the 2023 ASCO Annual Meeting, researchers found no significant survival benefit of neoadjuvant chemotherapy over upfront surgery in patients with resectable pancreatic cancer. Key Points: “Results of this trial do not support neoadjuvant FOLFIRINOX as standard of care in resectable pancreatic cancer.” Knut Jørgen Labori, MD, PhD, Oslo University Hospital, Norway
Oncology, Medical June 12th 2023